US20040147575A1 - Nitrate salts of antihypertensive medicines - Google Patents

Nitrate salts of antihypertensive medicines Download PDF

Info

Publication number
US20040147575A1
US20040147575A1 US10/671,746 US67174603A US2004147575A1 US 20040147575 A1 US20040147575 A1 US 20040147575A1 US 67174603 A US67174603 A US 67174603A US 2004147575 A1 US2004147575 A1 US 2004147575A1
Authority
US
United States
Prior art keywords
residue
formula
iii
xip
methyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US10/671,746
Inventor
Piero Soldato
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nicox SA
Original Assignee
Nicox SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nicox SA filed Critical Nicox SA
Priority to US10/671,746 priority Critical patent/US20040147575A1/en
Publication of US20040147575A1 publication Critical patent/US20040147575A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C211/00—Compounds containing amino groups bound to a carbon skeleton
    • C07C211/01—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms
    • C07C211/26—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring
    • C07C211/27—Compounds containing amino groups bound to a carbon skeleton having amino groups bound to acyclic carbon atoms of an unsaturated carbon skeleton containing at least one six-membered aromatic ring having amino groups linked to the six-membered aromatic ring by saturated carbon chains
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/30—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings containing hydroxy groups and carbon atoms of six-membered aromatic rings bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/22—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated
    • C07C215/28—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings
    • C07C215/38—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being unsaturated and containing six-membered aromatic rings with rings other than six-membered aromatic rings being part of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/12—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a ring other than a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/06—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted
    • C07C217/14—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/18—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/22—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one etherified hydroxy group and one amino group bound to the carbon skeleton, which is not further substituted the oxygen atom of the etherified hydroxy group being further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/34—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by halogen atoms, by trihalomethyl, nitro or nitroso groups, or by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C217/00—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton
    • C07C217/02—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C217/04—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C217/28—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines
    • C07C217/30—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring
    • C07C217/32—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted
    • C07C217/36—Compounds containing amino and etherified hydroxy groups bound to the same carbon skeleton having etherified hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having one amino group and at least two singly-bound oxygen atoms, with at least one being part of an etherified hydroxy group, bound to the carbon skeleton, e.g. ethers of polyhydroxy amines having the oxygen atom of at least one of the etherified hydroxy groups further bound to a carbon atom of a six-membered aromatic ring the six-membered aromatic ring or condensed ring system containing that ring being further substituted by carbon atoms having at least two bonds to oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/25—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to a hydrogen atom or to a carbon atom of an acyclic saturated carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/04—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C235/06—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being acyclic and saturated having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/42—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/44—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/58—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C235/60—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings and singly-bound oxygen atoms bound to the same carbon skeleton with carbon atoms of carboxamide groups and singly-bound oxygen atoms bound to carbon atoms of the same non-condensed six-membered aromatic ring with carbon atoms of carboxamide groups and singly-bound oxygen atoms, bound in ortho-position to carbon atoms of the same non-condensed six-membered aromatic ring having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
    • C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
    • C07C255/42—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms
    • C07C255/43—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by singly-bound nitrogen atoms, not being further bound to other hetero atoms the carbon skeleton being further substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/30—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/37—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C07C311/38—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton
    • C07C311/44—Sulfonamides, the carbon skeleton of the acid part being further substituted by singly-bound nitrogen atoms, not being part of nitro or nitroso groups having the sulfur atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring having sulfur atoms of sulfonamide groups and amino groups bound to carbon atoms of six-membered rings of the same carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/10—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms
    • C07D211/12—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with radicals containing only carbon and hydrogen atoms attached to ring carbon atoms with only hydrogen atoms attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
    • C07D211/90—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/18—Ring systems of four or more rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D237/00—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings
    • C07D237/26—Heterocyclic compounds containing 1,2-diazine or hydrogenated 1,2-diazine rings condensed with carbocyclic rings or ring systems
    • C07D237/30—Phthalazines
    • C07D237/34—Phthalazines with nitrogen atoms directly attached to carbon atoms of the nitrogen-containing ring, e.g. hydrazine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/50—Three nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/24—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D241/26—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with nitrogen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/10—1,2,5-Thiadiazoles; Hydrogenated 1,2,5-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/02—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements
    • C07D295/027—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring
    • C07D295/03—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms containing only hydrogen and carbon atoms in addition to the ring hetero elements containing only one hetero ring with the ring nitrogen atoms directly attached to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/06—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals
    • C07D295/073—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by halogen atoms or nitro radicals with the ring nitrogen atoms and the substituents separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/13—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/14—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D295/145—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/15—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with the ring nitrogen atoms and the carbon atoms with three bonds to hetero atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/18—Systems containing only non-condensed rings with a ring being at least seven-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline

Definitions

  • the present invention relates to compounds and their compositions to be used in the hypertension therapy and prophylaxis. More specifically it relates to the use of said hypertensives for systemic and local use, in particular for the cardiovascular area. More specifically the present invention relates to new antihypertensive compounds having an improved performance.
  • the known compounds of the prior art used in the hypertension treatment generally have a limited efficacy.
  • the hypertension treatment is usually carried out by administering to the patient the antihypertensives in association with other medicines active on the vascular system, such as for instance calcium-antagonists, diuretics, beta-blockers, ACE inhibitors.
  • the antihypertensive antagonists of the angiotensin (ex. Losartan), the calcium antagonists (ex. dihydropyridines), diuretics for example thiazidic derivatives, direct and undirect vasodilators (ex. Minoxidil, Zaprinast) are not able when used alone to assure the therapy success.
  • the Applicant has unexpectedly and surprisingly found compounds and pharmaceutical compositions usable in the treatment of the hypertension pathologies for systemic and local use, particularly of the cardiovascular area, with improved therapeutic profile, and without the side effects of the known hypertensive medicines.
  • It is an object of the present invention nitrate salts of compounds having an antihypertensive activity, or pharmaceutical compositions thereof, for systemic and local use, particularly to be used for the cardiovascular area, said compounds being characterized in that they contain at least a reactive group capable to be salified, said compounds being selected from the following classes:
  • R A1 ⁇ —O with R III A1 free valence, so as to form in combination with the carbon atom in 5 position a ketone group, R A1 together with R I A1 and the carbon atoms in 4 and 5 position of the heterocyclic ring in the compound of formula (A1b), with R IV A1 and R III A1 free valences, forms the aromatic ring having 6 carbon atoms containing a —COOH group:
  • R I A1 with R A1 , R IV A1 , R III A1 and the carbon atoms in 4 and 5 position of the heterocyclic ring of formula (A1b) forms the aromatic ring containing a COOH group (IXc),
  • R I A1 with R IV A1 and with the carbon atom in 4 position of the heterocyclic ring of formula (A1b) forms the following saturated ring having five carbon atoms:
  • R II A1 ⁇ —(CH 2 ) 3 —CH 3 , —O—CH 2 —CH 3 ;
  • R III A1 free valence with R IV A1 free valence forms a double bond between the carbon atoms in 4 and 5 position in the heterocyclic ring of formula (A1b),
  • R III A1 with R IV A1 , R I A1 and the carbon atoms in 4 and 5 position of the heterocyclic ring of formula (A1b) forms the aromatic ring containing a —COOH group (IXc);
  • R IV A1 free valence
  • R IV A1 along with R I A1 with the carbon atom in 4 position of the heterocyclic ring of formula (A1b) forms the saturated ring having five carbon atoms (IXd)
  • R IV A1 with R III A1 , R I A1 and the carbon atoms in 4 and 5 position of the heterocyclic ring of formula (A1b) forms the aromatic ring containing a —COOH group (IXc),
  • R IV A1 with R III A1 both free valences form a double bond between the carbon atoms in 4 and 5 position of the heterocyclic ring of formula (A1b);
  • Valsartan [0021] known as Valsartan
  • the precursors of this class are the following ones: 1(2H)-phthalazinone hydrazone (Hydralazine); 6-(1-piperidinyl)-2,4-pyrimidinediamine 3-oxide (Minoxidil); 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazol[4,3-d]pyrimidin-5-yl)-4-etoxyphenyl]sulphonyll-4-methyl-piperazine (Sildenafil), 2-(2-propyloxyphenyl)-8-azapurin-6-one (Zaprinast);
  • R I B1 and R II B1 are H, CH 3 ,
  • Y B1 can have the following meanings:
  • n and m equal to or different from each other, are 0, 1;
  • A is a tertiary carbon atom and contemporaneously W1 is free valence so as to form a double bond —CH ⁇ CH— between A and the carbon atom in 1′ position,
  • a in the ring having 5 atoms is a tertiary carbon atom containing a substituent such that with the carbon atom in 1′ position and with one of the two W1 or W2 radicals, the other radical being free valence, forms an aromatic ring having 6 carbon atoms according to the following formula:
  • W1 H, free valence, when W1 is free valence and A is a tertiary carbon atom as above defined, a double bond between A and the carbon atom in 1′ position is formed,
  • S 4 is a tertiary carbon atom which with the carbon atoms in 1 and 6 position of the aromatic ring of the radical (XIp), and with the following components of the formula (A3): the carbon atom —
  • N-phenyl-1,3,5-triazine-2,4-diamine (Amanozine), 3,5-diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide (Amiloride), N-(4-chlorophenyl)-1,3,5-triazine-2,4-diamine (Chlorazanyl), [3-methyl-4-oxo-5-(1-piperidinyl)-2-thiazolidinylidene]acetic acid ethyl ester (Etozolin), 6-hydrazino-3-piridazinecarboxamide (Hydracarbazine), 5-amino-2-[1-(3,4-dichlorophenyl)ethyl]-2,4-dihydro-3H-pyrazol-3-one (Muzolimine), 2-(2,2-dicylcohexylethyl)piperidine (Perhexiline), 6-phenyl-2
  • Class (A8) Apomorphine.
  • R A1 ⁇ —O and R III A1 free valence so as to form in combination with the carbon atom in 5 position of the heterocyclic ring of the formula (A1b) a ketonic group
  • R I A1 with R IV A1 and with the carbon atom in 4 position of the heterocyclic ring are such as to form the saturated ring having 5 carbon atoms (IXd), Irbesartan residue;
  • R II A1 ⁇ —O—CH 2 —CH 3
  • R A1 together with R I A1 and the carbon atoms in 4 and 5 position of the heterocyclic ring with R IV A1 and R III A1 free valences, are such as to form the aromatic radical containing a —COOH group (IXc), Candesartan residue;
  • the preferred compounds of the A2 class are the following:
  • the preferred compounds of the (A3) class are the following:
  • R IV B1 is the naphthalenic residue (XIm) linked by the carbon atom in 1 position to X B1 Propranolol residue;
  • class (A7) the preferred compounds are the following:
  • Class A1b Losartan
  • Class A2) Sildenafil, Zaprinast
  • Class A3) Atenolol, Labetalol, Timolol, Prazosin, Terazosin, Propanolol
  • Class A4) Nicardipine, Nifedipine, Nimodipine
  • Class A7) Chlorothiazide, Amiloride, Furosemide.
  • compositions according to the present invention also the isomers of the compounds belonging to the above described classes can be used.
  • Example of isomers are cis-, trans-, optical isomer D and L or the racemic, enantiomer.
  • one isomeric form has higher activity with respect to the other, e.g., D form with respect to L form or viceversa.
  • the salts of the compounds belonging to these classes contain at least a nitrate ion mole/compound mole.
  • the ratio between the nitrate ion moles and the precursor ones is unitary. Salts having higher molar ratio are obtained when in the molecule other aminic groups basic enough to be salified are present.
  • the salts of the present invention are formulated in the corresponding pharmaceutical compositions according to the well known techniques in the field, together with the usual excipients; see for example the “Remington's Pharmaceutical Sciences 15a Ed.” volume.
  • the salt is prepared by dissolving the substance in the solvent at a concentration preferably equal to or higher than 10% w/v, adding the amount of concentrated nitric acid corresponding to the moles of salifiable aminic groups present in the compound.
  • the nitric acid is preferably diluted in the same solvent.
  • the mixture is cooled to temperatures in the range 20° C.-0° C.
  • the product is generally recovered by filtration and washed with the solvent.
  • the substance is not very soluble, or it is available as a not very soluble salt in the above mentioned solvents
  • the corresponding mixtures with hydroxylated solvents can be used.
  • solvents are methyl alcohol, ethyl alcohol and water. Precipitation can be quickened by diluting then the so obtained mixture, after the addition of nitric acid, with an apolar solvent.
  • the starting product is salified with hydrochloric acid
  • the starting product is a salt
  • the base is then extracted by a suitable organic solvent (for example halogenated solvents, esters, ethers), which is then dried.
  • the organic solution is evaporated and then one proceeds according to the preceding preparation methods, by dissolving the base in acetonitrile or in the other above mentioned solvents.
  • nitrate salts can be obtained also by using precursors of the described classes containing in the molecule a —ONO 2 group bound by a linking bridge prepared as described in the European patent 759,899 in the name of the Applicant herein incorporated by reference.
  • a Valsartan solution (3.48 g, 8 mmoles) is prepared by dissolving in a mixture of acetonitrile (30 ml) and tetrahydrofuran (10 ml). Nitric acid diluted in acetonitrile is added at cold (2 ml taken from a solution obtained by adding to 2.7 ml of 65% nitric acid in acetonitrile and bringing to the final volume of 10 ml). After 30 minutes ethyl ether (100 ml) is slowly added at the same temperature (+4° C.). A precipitate is formed which is filtered, washed with ethyl ether and dried under vacuum. A white amorphous solid (3.1 g) is obtained.
  • Elementary analysis (C 24 H 30 N 6 O 6 ): calc. (%) C 57.82 H 6.07 N 16.86 found (%) C 58.02 H 6.02 N 16.77
  • the compounds at a dose of 10 mg/kg and the corresponding carrier have been administered to the guinea pigs (groups of 6 animals each) by intraperitoneal route for three consecutive days.
  • the animals were prepared according to the method of Del Soldato et al. J. Pharmacol. Methods 5 279 1981. 45 minutes later 0.1 ml of a Capsaicin saline solution (1 ⁇ g/Kg) was injected to the anumals intravenously. The tidal air variation before and after the Capsaicin administration was measured by a Konzett apparatus, modified as described in the above mentioned reference, connected to a polygraphic system.
  • the compounds have been administered in physiological solution.
  • the control group has been treated with the carrier (physiologic solution) only.
  • the vaso-relaxing activity of Sildenafil nitrate was determined by using the experimental model of the prostatic deferent vessels constriction, induced by submaximum electric stimulation (D. A. Taylor et al., J. Pharmacol. Exp. Ther. 224, 40-45 1983), in rats treated with N W -nitro-L-arginine-methyl ester (L-NAME) as described by Ribeiro et al., Hypertension, 20, 298, 1992.
  • a daily dose of 10 mg/kg of Sildenafil nitrate, of Sildenafil or of the carrier were sacrificed and the prostatic part of the deferent vessel was remouved, dipped in a physiologic solution at 37° C., and contracted by transmural stimulation (95% of the maximum stimulation, 0.2 Hz).
  • the myorelaxing activity of the nitrate salt is greater than that of the precursor reference compound.
  • the compounds have been administered in physiologic solution.
  • the control group has been treated with the carrier (physiological solution) only.
  • the compounds have been administered in a physiologic solution.
  • the control group was treated with the carrier (physiologic solution) only.
  • vasorelaxing activity is expressed as the reduction of the contractive neurogenic response, determined within 5 minutes from the addition of the tested compound at a 10 ⁇ 6 M concentration.
  • TABLE VI Average arterial Effect on the pressure vasoconstriction Treatment (mm Hg) % (n 5) Carrier 170 ⁇ 7 100 Minoxidil.HNO 3 110 ⁇ 6 5 Minoxidil 132 ⁇ 6 18
  • the Amiloride pharmacological profile has been determined by using the following experimental models: the arterial hypertension produced by L-NAME, and the diuretic effect.
  • Nitric acid 65% (0.75 ml) is added to a Perhexiline solution (3.02 g, 10.9 mmole) in acetonitrile and methanol (10 ml), cooled at 0° C.
  • the obtained solution is maintained under magnetic stirring at 0° C. for 30 minutes, then at room temperature for further 30 minutes.
  • the solvent is evaporated under reduced pressure and the crude product is suspended in ethylic ether and then filtered.

Abstract

Nitric acid salts with medicines having an antihypertensive activity.

Description

  • The present invention relates to compounds and their compositions to be used in the hypertension therapy and prophylaxis. More specifically it relates to the use of said hypertensives for systemic and local use, in particular for the cardiovascular area. More specifically the present invention relates to new antihypertensive compounds having an improved performance. [0001]
  • The known compounds of the prior art used in the hypertension treatment generally have a limited efficacy. The hypertension treatment is usually carried out by administering to the patient the antihypertensives in association with other medicines active on the vascular system, such as for instance calcium-antagonists, diuretics, beta-blockers, ACE inhibitors. For example the antihypertensive antagonists of the angiotensin (ex. Losartan), the calcium antagonists (ex. dihydropyridines), diuretics (for example thiazidic derivatives, direct and undirect vasodilators (ex. Minoxidil, Zaprinast) are not able when used alone to assure the therapy success. [0002]
  • It is necessary moreover to point out that some antihypertensives cause side effects for the respiratory apparatus, such as bronchoconstriction, dyspnea. For instance the antihypertensive used in the angina pectoris and cardiac arrhythmias treatment, for instance Timolol and Propanolol, give said side effects. [0003]
  • Other antihypertensives induce vasodilatation through phosphodiesterases inhibition and show side effects for various apparatuses (gastrointestinal, cardiovascular, ocular, etc.) See for instance Sildenafil and Zaprinast. [0004]
  • The need was felt to have available compositions active in the hypertension pathology treatment for systemic and local use, in particular of the cardiovascular area, with improved therapeutic profile. In particular the need was felt, moreover, to have available antihypertensive medicines having a beta-blocking or antiphosphodiesterasic action with lower side effects. [0005]
  • The Applicant has unexpectedly and surprisingly found compounds and pharmaceutical compositions usable in the treatment of the hypertension pathologies for systemic and local use, particularly of the cardiovascular area, with improved therapeutic profile, and without the side effects of the known hypertensive medicines. [0006]
  • It is an object of the present invention nitrate salts of compounds having an antihypertensive activity, or pharmaceutical compositions thereof, for systemic and local use, particularly to be used for the cardiovascular area, said compounds being characterized in that they contain at least a reactive group capable to be salified, said compounds being selected from the following classes: [0007]
  • Class (A1b): [0008]
    Figure US20040147575A1-20040729-C00001
  • R[0009] A1═—O with RIII A1 free valence, so as to form in combination with the carbon atom in 5 position a ketone group, RA1 together with RI A1 and the carbon atoms in 4 and 5 position of the heterocyclic ring in the compound of formula (A1b), with RIV A1 and RIII A1 free valences, forms the aromatic ring having 6 carbon atoms containing a —COOH group:
    Figure US20040147575A1-20040729-C00002
  • R[0010] I A1═H, Cl;
  • R[0011] I A1 with RA1, RIV A1, RIII A1 and the carbon atoms in 4 and 5 position of the heterocyclic ring of formula (A1b) forms the aromatic ring containing a COOH group (IXc),
  • R[0012] I A1 with RIV A1 and with the carbon atom in 4 position of the heterocyclic ring of formula (A1b) forms the following saturated ring having five carbon atoms:
    Figure US20040147575A1-20040729-C00003
  • R[0013] II A1═—(CH2)3—CH3, —O—CH2—CH3;
  • R[0014] III A1═H, free valence,
  • R[0015] III A1 free valence with RIV A1 free valence forms a double bond between the carbon atoms in 4 and 5 position in the heterocyclic ring of formula (A1b),
  • R[0016] III A1 with RIV A1, RI A1 and the carbon atoms in 4 and 5 position of the heterocyclic ring of formula (A1b) forms the aromatic ring containing a —COOH group (IXc);
  • R[0017] IV A1=free valence, RIV A1 along with RI A1 with the carbon atom in 4 position of the heterocyclic ring of formula (A1b) forms the saturated ring having five carbon atoms (IXd),
  • R[0018] IV A1 with RIII A1, RI A1 and the carbon atoms in 4 and 5 position of the heterocyclic ring of formula (A1b) forms the aromatic ring containing a —COOH group (IXc),
  • R[0019] IV A1 with RIII A1 both free valences form a double bond between the carbon atoms in 4 and 5 position of the heterocyclic ring of formula (A1b);
  • Class (A1c): [0020]
    Figure US20040147575A1-20040729-C00004
  • known as Valsartan; [0021]
  • Class (A2): [0022]
  • the precursors of this class are the following ones: 1(2H)-phthalazinone hydrazone (Hydralazine); 6-(1-piperidinyl)-2,4-pyrimidinediamine 3-oxide (Minoxidil); 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazol[4,3-d]pyrimidin-5-yl)-4-etoxyphenyl]sulphonyll-4-methyl-piperazine (Sildenafil), 2-(2-propyloxyphenyl)-8-azapurin-6-one (Zaprinast); [0023]
  • Class (A3): [0024]
    Figure US20040147575A1-20040729-C00005
  • R[0025] I B1 and RII B1, equal to or different from each other, are H, CH3,
    Figure US20040147575A1-20040729-C00006
  • In the formula (XId) t 0, 1. [0026]
  • In the formula (XIe) Y[0027] B1 can have the following meanings:
    Figure US20040147575A1-20040729-C00007
  • in the formula (XIf) Z=H, —OCH[0028] 3;
  • in the formula (A3): [0029]
  • X[0030] B1═—O—, —S—;
  • n and m, equal to or different from each other, are 0, 1; [0031]
    Figure US20040147575A1-20040729-C00008
    Figure US20040147575A1-20040729-C00009
  • in the formula (XIp): [0032]
  • S[0033] 1═H, CN, OCH3, CH3, —CH2—CH3, —O—CH2—CONH—CH3, —COCH3, —CO—(CH2)2—CH3, —O—CH2—CH═CH2, —CH2—CH═CH2, cyclopentyl, or
    Figure US20040147575A1-20040729-C00010
  • S[0034] 2═H, CH3, Cl, —SOCH3, —CONH2;
  • S[0035] 1 with S2 and the carbon atoms in 2 and 3 position of the C6 aromatic ring of the same radical (XIp) forms the following ring:
    Figure US20040147575A1-20040729-C00011
  • wherein: [0036]
  • [(*) atom adjacent to the aromatic ring of the formula XIp[0037] VII]
  • B═—CH[0038] 2—, —NH—, —CH═CH—, (*)-CO—CH2—;
  • A═—O—, (*)-CH[0039] 2—CH(OH)—, (*)-O—CH2—, (*)-S—CH2—, —CH2—CH2—, —CH2—,
  • A is a tertiary carbon atom and contemporaneously W1 is free valence so as to form a double bond —CH═CH— between A and the carbon atom in 1′ position, [0040]
  • A in the ring having 5 atoms (XIp[0041] VII) is a tertiary carbon atom containing a substituent such that with the carbon atom in 1′ position and with one of the two W1 or W2 radicals, the other radical being free valence, forms an aromatic ring having 6 carbon atoms according to the following formula:
    Figure US20040147575A1-20040729-C00012
  • W1=H, free valence, when W1 is free valence and A is a tertiary carbon atom as above defined, a double bond between A and the carbon atom in 1′ position is formed, [0042]
  • W1 together with W2, the carbon-atom in 1′ position and the substituent A forms an aromatic ring having 6 carbon atoms; [0043]
  • W2=free valence, H, OH, —CH[0044] 3, —ONO2, —O which with W1=free valence and the carbon atom in 1′ position forms a ketone group,
  • W2 together with W1, the carbon atom in 1′ position and the substituent A forms an aromatic ring having 6 carbon atoms; [0045]
  • S[0046] 3═H, F, Cl, OH, NO2, —CH2—CO—NH2, —(CH2)2—OCH3, —NH—COCH3, —CH2—O—CH2—CH2—O—CH(CH3)2, —CH2—CH2—COOCH3, —NH—CO—N(C2H5)2, —NH—CO—(CH2)2—CH3, —NH—SO2—CH3, —NH—CO—NH-[cyclohexyl], —CH2—CH2—O—CH2-[cyclopropyl];
  • S[0047] 4═H, Cl, —CH2—CH2— which with the carbon atoms in 1 and 6 position of the aromatic ring of the same radical (XIp) and with XB1 in the formula (A3) equal to oxygen, being contemporaneously m=n=1 and RVII B1 free valence, forms the following ring:
    Figure US20040147575A1-20040729-C00013
  • S[0048] 4 is a tertiary carbon atom which with the carbon atoms in 1 and 6 position of the aromatic ring of the radical (XIp), and with the following components of the formula (A3): the carbon atom —|C|n— (n=1), the radical XB1 equal to oxygen (m=1), and RVII B1 with RVI B1 free valences, forms the following ring:
    Figure US20040147575A1-20040729-C00014
  • R[0049] VI B1═H, free valence;
  • R[0050] VII B1═H, free valence;
  • Other compounds belonging to this class are the following: 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]benzamide (Labetalol), 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine (Terazosin), 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine (Prazosin); [0051]
  • Class (A4): [0052]
  • the following groups of compounds belong to this class: [0053]
  • (A4a): [0054]
  • β-[(2-methylpropoxy)methyl]-N-phenyl-N-(phenylmethyl)-1-pyrrolidineethanamine (Bepridil), (2S-cis)-3-(acetyloxy)-8-chloro-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxy-phenyl)-1,5-benzothiazepin-4(5H)-one (Clentiazem), (2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4 (5H)-one (Diltiazem), γ-phenyl-N-(1-phenylethyl)benzene-propanamine (Fendiline), α-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4,5-tri-methoxy-α-(1-methylethyl)-benzeneacetonitrile (Gallopamil), (1S-cis)methoxyacetic acid 2-[2-[[3-(1H-benzimidazol-2-yl)propyl]methylamino]ethyl]-6-fluoro-1,2,3,4-tetrahydro-1-(1-methylethyl)-2-naphthalenyl ester (Mibefradil), N-(1-methyl-2-phenylethyl)-γ-phenylbenzenepropanamine (Prenylamine), (R)-2-[2-[3-[[2-(1,3-bezodioxol-5-yloxy)ethyl]methylamino]propoxy]-5-methoxyphenyl]-4-methyl-2H-1,4-benzothiazin-3(4H)-one (Semotiadil), N-(1,1-dimethylethyl)-α-methyl-γ-phenylbenzenepropanamine (Terodiline), α-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methylamino]propyl]-3,4-dimethoxy-α-(1-methylethyl)-benzeneacetonitrile (Verapamil); [0055]
  • (A4b): [0056]
  • 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridynedicarboxylic acid 3-ethyl 5-methyl ester (Amlodipine), 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 2-oxopropyl ester (Aranidipine), [S—(R*,R*)]-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 1-(phenylmethyl)-3-pirrolidinyl ester (Barnidipine), (R*,R*)-±-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 1-(phenylmethyl)-3-piperidinyl ester (Benidipine), (E)-±-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxilic acid 2-methoxyethyl 3-phenyl-2-propenyl ester (Cilnidipine), 5-(5,5-dimethyl-1,3,2-dioxaphosphorinane-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridine-carboxylic acid 2-[phenyl(phenylmethyl)amino]ethyl ester P-oxide (Efonidipine), ±-4-(1,3-benzodioxol-4-yl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 2-[[(4-fluoro-phenil)methyl]methylamino]ethyl 1-methylethyl ester (Elgodipine), 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxilic acid ethyl methyl ester (Felodipine), 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 5-methyl 3-(1-methyl)ethyl ester (Isradipine), (E)-4-[2-[3-(1,1-dimethylethoxy)-3-oxo-1-propenyl]phenyl]-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid diethyl ester (Lacidipine), 1,4-dihydro-2,6-dimethyl-4-(3-nitro-phenyl)-3,5-pyridinedi-carboxilic acid 2-[(3,3-diphenyl-propyl)methylamino]-1,1-dimethylethyl methyl ester (Lercanidipine), 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxilic acid 2-[4-(diphenylmethyl)-1-piperazinyl]ethyl methyl ester (Manidipine), 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 2[methyl(phenylmethyl)amino]ethyl ester (Nicardipine), 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester (Nifedipine), 2-cyano-1,4-dihydro-6-methyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 3-methyl 5-(1-methylethyl)ester (Nilvadipine), 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester (Nimodipine), 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 2-methylpropyl ester (Nisoldipine), 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester (Nitrendipine); [0057]
  • (A4c): [0058]
  • 1-(diphenylmethyl)-4-(3-phenyl-2-propenyl)piperazine (Cinnarizine), (E)-1-[bis(4-fluorophenyl)methyl]4-(3-phenyl-2-propenyl)piperazine (Flunarizine), 4-[4,4-bis(4-fluorophenyl)butyl]-N-(2,6-dimethylphenyl)-1-piperazineacetamide (Lidoflazine), 1-[bis(4-fluorophenyl)methyl]-4-[(2,3,4-trimethoxyphenyl)methyl]piperazine (Lomerizine); [0059]
  • (A4d): [0060]
  • N,N-dimethyl-3-[[1-(phenylmethyl)-cycloheptyl]oxy]-1-propanamine (Bencyclane), 1-[2-[2-(diethylamino)ethoxy]phenyl]-3-phenyl-1-propanone (Etafenone), 3,4-dimethoxy-N-methyl-N-[3-[4-[(2-(1-methylethyl)-1-indolizinyl]sulphonyl]phenoxy]-propyl]benzeneethanamine (Fantofarone); [0061]
  • Class (A7): [0062]
  • the following groups of compounds belong to this class: [0063]
  • (A7a): [0064]
  • 6-chloro-3,4-dihydro-3-[(2-propenylthio)methyl]-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide (Althiazide), 3,4-dihydro-3-(phenylmethyl)-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide (Bendroflumethiazide), (6-chloro-3-[[(phenylmethyl)thio]methyl]-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide (Benzthiazide), 6-chloro-3,4-dihydro-3-(phenylmethyl)-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide (Benzylhydrochlorothiazide), 6-chloro-3,4-dihydro-3-(2-methylpropyl)-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide (Buthiazide), 6-chloro-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide (Chlorothiazide), 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzebesulphonamide (Chlorthalidone), 6-chloro-3-(cyclopentylmethyl)-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide (Cyclopenthiazide), 3-bicyclo [2.2.1]-hept-5-en-2-yl-6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide (Cyclothiazide), 6-chloro-3,4-dihydro-3-[[(2,2,2-trifluoroethyl)tio]methyl]-2H-1,2,4-benzo-thiadiazine-7-sulphonamide 1,1-dioxide (Epithiazide), 6-chloro-3-ethyl-3,4-di-hydro-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide (Ethiazide), 7-chloro-1,2,3,4-tetrahydro-4-oxo-2-phenyl-6-quinazolinesulphonamide (Fenquizone), 3-(aminosulphonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)benzamide (Indapamide), 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide (Hydrochlorothiazide), 3,4-dihydro-6-(trifluoromethyl)-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide (Hydroflumethiazide), 6-chloro-3-(chloromethyl)-3,4-dihydro-2-methyl-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide (Methyclothiazide), 3,4-dihydro-6-methyl-2H-1-benzothiopyran-7-sulphfonamide 1,1-dioxide (Methycrane), 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazoline-sulphonamide (Metolazone), 6-chloro-3-[(4-fluorophenyl)-methyl]-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide (Paraflutizide), 6-chloro-3,4-dihydro-2-methyl-3-[[(2,2,2-trifluoroethyl)thio]methyl]-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide (Polythiazide), 7-chloro-2-ethyl-1,2,3,4-tetrahydro-4-oxo-6-quinazolinesulphonamide (Quinethazone), 6-chloro-3,4-dihydro-3-trichloromethyl-2H-1,2,4-benzothadiazine-7-sulphonamide 1,1-dioxide (Teclothiazide), 6-chloro-3-(dichloromethyl)-3,4-dihydro-2H-1,2,4-benzothadiazine-7-sulphfonamide 1,1-dioxide (Trichlormethiazide); [0065]
  • (A7b): [0066]
  • 3,7-dihydro-1,3-dimethyl-7-(4-morpholinylmethyl)-1H-purine-2,6-dione (7-Morpholinomethyltheophylline), 3,7-dihydro-1-(2-hydroxypropyl)-3,7-dimethyl-1H-purine-2,6-dione (Protheobromine), 3,7-dihydro-3,7-dimethyl-1H-purine-2,6-dione (Theobromine); [0067]
  • (A7c): [0068]
  • 6-amino-3-ethyl-1-(2-propenyl)-2,4(1H,3H)-pyrimidinedione (Aminometradine), 6-amino-3-methyl-1-(2-methyl-2-propenyl)-2,4(1H,3H)-pyrimidinedione (Amisometradine); [0069]
  • (A7d): [0070]
  • N-phenyl-1,3,5-triazine-2,4-diamine (Amanozine), 3,5-diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide (Amiloride), N-(4-chlorophenyl)-1,3,5-triazine-2,4-diamine (Chlorazanyl), [3-methyl-4-oxo-5-(1-piperidinyl)-2-thiazolidinylidene]acetic acid ethyl ester (Etozolin), 6-hydrazino-3-piridazinecarboxamide (Hydracarbazine), 5-amino-2-[1-(3,4-dichlorophenyl)ethyl]-2,4-dihydro-3H-pyrazol-3-one (Muzolimine), 2-(2,2-dicylcohexylethyl)piperidine (Perhexiline), 6-phenyl-2,4,7-pteridinetriamine (Triamterene), 3-(aminosulphonyl)-5-(butylamino)-4-phenoxybenzoic acid (Bumetanide), 5-(amino sulphfonyl)-4-chloro-2-[(2-furanylmethyl)amino]benzoic acid (Furosemide), N-[[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulphonamide (Torasemide); [0071]
  • Class (A8): Apomorphine. [0072]
  • The preferred compounds in the (A1b) class are the following: when X[0073] A1═(IXa), RA1═CH2OH, RI A1═Cl, RIII A1═RIV A1=free valences forming a —CH═CH— double bond with the carbon atoms in 4 and 5 position of the heterocyclic ring of the formula (A1b), RII A1═—(CH2)3—CH3, Losartan residue;
  • as in Losartan but with R[0074] A1═—O and RIII A1 free valence, so as to form in combination with the carbon atom in 5 position of the heterocyclic ring of the formula (A1b) a ketonic group, RI A1 with RIV A1 and with the carbon atom in 4 position of the heterocyclic ring are such as to form the saturated ring having 5 carbon atoms (IXd), Irbesartan residue;
  • as in Losartan but with R[0075] II A1═—O—CH2—CH3, RA1 together with RI A1 and the carbon atoms in 4 and 5 position of the heterocyclic ring with RIV A1 and RIII A1 free valences, are such as to form the aromatic radical containing a —COOH group (IXc), Candesartan residue;
  • as in Losartan but with X[0076] A1═—COOH, RA1═(IXb), RI A1═H, RIV A1 and RIII A1 free valences form a double bond between the carbon atoms in 4 and 5 position in the heterocyclic ring of the formula (A1b), Eprosartan residue.
  • The preferred compounds of the A2 class are the following: [0077]
  • 1-[[3-(4,7-dihydro-1-methyl-7-oxo-3-propyl-1H-pyrazol[4,3-d]-pyrimidin-5-yl)-4-ethoxyphenyl]sulfonyll-4-methyl-piperazine (Sildenafil), 2-(2-propyloxyphenyl)-8-azapurin-6-one (Zaprinast). [0078]
  • The preferred compounds of the (A3) class are the following: [0079]
  • when R[0080] I B1═H, RII B1 and RIII B1═CH3, RV B1═H, RVI B1═RVII B1═H, m=n=1, XB1═—O—, RIV B1═(XIp) wherein S1═S2═S4═H, S3=—CH2—CO—NH2, Atenolol residue;
  • as in Atenolol but with R[0081] IV B1═(XIs), Befunolol residue;
  • as in Atenolol, but with S[0082] 3═S2═S4═H, S1═—CH2—CH═CH2, Alprenolol residue;
  • as in Atenolol, but with S[0083] 1═COCH3, S3═—NH—CO—(CH2)2—CH3, S2═S4═H, Acebutolol residue;
  • as in Atenolol, but with S[0084] 3═—CH2—CH2—O—CH2-(cyclopropyl), Betaxolol residue;
  • as in Atenolol but with S[0085] 3═—CH2—O—CH2—CH2—O—CH(CH3)2, Bisoprolol residue;
  • as in Alprenolol but with S[0086] 1═(XIpII) and R1 B1═CH3, Bufetolol residue;
  • as in Bufetolol, but with S[0087] 1═—CN, Bunitrolol residue;
  • as in Bufetolol, but with S[0088] 1═H, S4═Cl, S2═CH3, Bupranolol residue;
  • as in Bufetolol but with S[0089] 1═—CO—(CH2)2—CH3, S3═F, Butofilolol residue;
  • as in Atenolol but with R[0090] IV B1═(XIpVIII), wherein B═—NH—, Carazolol residue;
  • as in Bufetolol, but with R[0091] IV B1═(XIpVII) wherein A=-CH2—CH2—, B═—NH—, W2=-O which with W1=free valence and the carbon atom in 1′ position forms a ketonic group, Carteolol residue;
  • as in Bufetolol but with S[0092] 3═—NH—CO—N(C2H5)2, S1═—CO—CH3 Celiprolol residue;
  • as in Bufetolol but with S[0093] 1═—O—CH2—CONH—CH3, Cetamolol residue;
  • as in Bupranolol, but with S[0094] 2═Cl Cloranolol residue;
  • as in Atenolol but with S[0095] 3═—CH2—CH2—COOCH3, Esmolol residue;
  • as in Atenolol but with R[0096] IV B1═(Xiu) Indenolol residue;
  • as in Carteolol, but in R[0097] IV B1═(XIpVII) A=-CH2—, B═—COCH2—, W1=W2=H, Levobunolol residue;
  • as in Carteolol but with R[0098] I B1═H and in RIV B1═(XIpVII) A is a tertiary carbon atom and W1 free valence, so as to form a —CH═CH— double bond between A and the carbon atom in 1′ position of (XIpVII), W2=CH3, Mepindolol residue;
  • as in Atenolol, but with S[0099] 3═—(CH2)2—OCH3, Metoprolol residue;
  • as in Carteolol but in R[0100] IV B1═(XIpVI) A=-CH2—CH(OH)—, B═—CH2—, W2=OH, W1=H, Nadolol residue;
  • as in Atenolol but with S[0101] 3═NO2, Nifenalol residue;
  • as in Mepindolol but in R[0102] IV B1═(XIpVII) A=-O—CH2—, B═—CH2—, W2=—ONO2, W1=H, Nipradilol residue;
  • as in Alprenolol, but with S[0103] 1═—O—CH2—CH═CH2, Oxprenolol residue;
  • as in Bufetolol, but with S[0104] 1=cyclopentyl, Penbutolol residue;
  • as in Mepindolol but with W2=H, Pindolol residue; [0105]
  • as in Atenolol but with S[0106] 3═—NH—COCH3, Practolol residue;
  • as in Bufetolol but with S[0107] 1═H, S3═—NH—CO—NH-(cyclohexyl), Talinolol residue;
  • as in Nipradilol but with R[0108] I B1═CH3, A=-S—CH2— and W2=H, Tertatolol residue;
  • as in Tertatolol but with R[0109] IV B1═(XIn), Tilisolol residue;
  • as in Bufetolol but with R[0110] IV B1═(XIo), Timolol residue;
  • as in Bufetolol but with S[0111] 1═S2═CH3, Xibenolol residue;
  • as in Xibenolol but with R[0112] I B1═S, ═H, Toliprolol residue;
  • as in Toliprolol, but with R[0113] II B1═H and RIII B1═(XIa), Bevantolol residue;
  • as in Carazolol but with R[0114] II B1═H and RIII B1═(XIb), Carvedilol residue;
  • when in the (A3) formula R[0115] I B1═RII B1═RIII B1═CH3, RV B1═(XIh), n=m=1, RVI B1═RVIIBB1═H, XB1═—O—, RIV B1═(XIg), Bopindolol residue;
  • as in Bufetolol but with R[0116] IV B1═(XIt), Bucumolol residue;
  • when in the (A3) formula m=n=0 and R[0117] IV B1═(XIz) RI B1═RII B1═RIII B1═CH3, RV B1═H, Bufuralol residue;
  • as in Atenolol but with R[0118] III B1═(XIe) with YB1═H, n=m=0, RIV B1═(XIi) Butidrine residue;
  • as in Butidrine, but with R[0119] III B1═(XIe) with YB1═(XIf) with Z=H, RIV B1═(XIp) wherein S3═OH and S2═CONH2, S1═S4═H, Dilevalol residue;
  • as in Bevantolol but with S[0120] 2═H, S1═CN, RIII B1═(XIc), Epanolol residue;
  • as in Butidrine but with R[0121] III B1═CH3, RIV B1═(XIm), wherein the naphthalenic residue is linked by the carbon atom in 2 position to the carbon atom bringing the —ORIV B1 substituent, Pronethalol residue;
  • as in Pronethalol but with m=1 and X[0122] B1═—O—, and RIV B1 is the naphthalenic residue (XIm) linked by the carbon atom in 1 position to XB1 Propranolol residue;
  • as in Pronethalol but with R[0123] IV B1═(XIp) with S1═S2═S4═H and S3═—NH—SO2—CH3, Sotalol residue;
  • as in Dilevalol but with S[0124] 2═—SOCH3, and in para position to the other aromatic ring (form. XIf) Z=—OCH3, Sulfinalol residue;
  • when in the (A3) formula R[0125] I B1═RII B1═H, RIII B1═(XId) with t=1, RV B1═H, n=m=0, RIV B1═(XId) with t=0, Nebivolol residue;
  • 2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]benzamide (Labetalol), 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine (Terazosin), 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine (Prazosin), benzonitrile,2-[2-hydroxy-3-[[2-(1H-indol-3-yl)-1,1-dimethylethyl]amino]propoxy (Bucindolol). [0126]
  • In the (A4) class the preferred compounds are the following: [0127]
  • (A4a): [0128]
  • (2s-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-dihydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one (Diltiazem), α-[3-[[2-(3,4-dimethoxyphenyl)ethyl]methyl amino]propyl]-3,4-dimethoxy-α-(1-methylethyl)-benzeneacetonitrile (Verapamil); [0129]
  • (A4b): [0130]
  • 2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-dihydro-6-methyl-3,5-pyridinedicarboxylic acid 3-ethyl 5-methyl ester (Amlodipine), 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid ethyl methyl ester (Felodipine) 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 5-methyl 3-(1-methyl)ethyl ester (Isradipine), Lercanidipine, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 2[methyl(phenylmethyl)amino]ethyl ester (Nicardipine), 1,4-dihydro-2,6-(2-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid dimethyl ester (Nifedipine), 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester (Nimodipine), 1,4-dihydro-2,6-dimethyl-4-(2-nitrophenyl)-3,5-pyridinedicarboxylic acid methyl 2-methyl-propyl ester (Nisoldipine), 1,4-dihydro-2,6-dimethyl-4-(3-nitro-phenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester (Nitrendipine); [0131]
  • (A4c): [0132]
  • (E)-1-[bis(4-fluorophenyl)methyl]4-(3-phenyl-2-propenyl)piperazine (Flunarizine). [0133]
  • In class (A7) the preferred compounds are the following: [0134]
  • (A7a): [0135]
  • 6-chloro-2H-1,2,4-benzothiadiazine-7-sulphonamide1,1-dioxide (Chlorothiazide), 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzebesulphonamide (Chlorthalidone), 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide (Hydrochlorothiazide), 3-(aminosulfonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)benzamide (Indapamide), 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulphonamide (Metolazone), 7-chloro-2-ethyl-1,2,3,4-tetrahydro-4-oxo-6-quinazolinesulphonamide (Quinethazone), [0136]
  • (A7d): [0137]
  • 3,5-diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide (Amiloride), 6-phenyl-2,4,7-pteridinetriamine (Triamterene), 3-(aminosulphonyl)-5-(butylamino)-4-phenoxybenzoic acid (Bumetanide), 5-(amino sulphonyl)-4-chloro-2-[(2-furanylmethyl)amino]benzoic acid (Furosemide), N-[[(1-methylethyl)amino-]carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulphonamide (Torasemide). [0138]
  • Particularly preferred compounds according to the present invention are the following: [0139]
    Class A1b): Losartan;
    Class A2): Sildenafil, Zaprinast;
    Class A3): Atenolol, Labetalol, Timolol, Prazosin,
    Terazosin, Propanolol;
    Class A4): Nicardipine, Nifedipine, Nimodipine;
    Class A7): Chlorothiazide, Amiloride, Furosemide.
  • The precursors of the salts belonging to the above mentioned classes are prepared according to the methods described in “The Merck Index 12a Ed.” (1996), herein incorporated by reference. The Zaprinast preparation method is described in the DE patent 2,162,096. The Bucindolol preparation method is described in the G.B. patent 2,001,633. [0140]
  • In the compositions according to the present invention also the isomers of the compounds belonging to the above described classes can be used. Example of isomers are cis-, trans-, optical isomer D and L or the racemic, enantiomer. In general one isomeric form has higher activity with respect to the other, e.g., D form with respect to L form or viceversa. [0141]
  • The salts of the compounds belonging to these classes contain at least a nitrate ion mole/compound mole. Preferably the ratio between the nitrate ion moles and the precursor ones is unitary. Salts having higher molar ratio are obtained when in the molecule other aminic groups basic enough to be salified are present. [0142]
  • The salts of the present invention are formulated in the corresponding pharmaceutical compositions according to the well known techniques in the field, together with the usual excipients; see for example the “Remington's Pharmaceutical Sciences 15a Ed.” volume. [0143]
  • The dose of the invention salts in their pharmaceutical compositions are the same, and generally lower than those of their precursors of the mentioned classes. [0144]
  • The salts of the present invention are obtainable according to one of the following methods: [0145]
  • When the substance to be salified is available as free base or as a corresponding salt soluble in an organic solvent, which preferably does not contain hydroxyl groups, for example acetonitrile, ethyl acetate, tetrahydrofuran, etc., the salt is prepared by dissolving the substance in the solvent at a concentration preferably equal to or higher than 10% w/v, adding the amount of concentrated nitric acid corresponding to the moles of salifiable aminic groups present in the compound. The nitric acid is preferably diluted in the same solvent. Preferably during and after the addition the mixture is cooled to temperatures in the range 20° C.-0° C. The product is generally recovered by filtration and washed with the solvent. [0146]
  • When on the contrary the substance is not very soluble, or it is available as a not very soluble salt in the above mentioned solvents, the corresponding mixtures with hydroxylated solvents can be used. Examples of such solvents are methyl alcohol, ethyl alcohol and water. Precipitation can be quickened by diluting then the so obtained mixture, after the addition of nitric acid, with an apolar solvent. [0147]
  • When the starting product is salified with hydrochloric acid, it is possible to prepare the salt with nitric acid directly adding silver nitrate to the compound solution. After filtering silver chloride, the solution is concentrated and cooled to recover the nitrate salt. [0148]
  • When the starting product is a salt, it is also possible to liberate the corresponding base by a treatment with a sodium or potassium bicarbonate or carbonate saturated solution, or with a sodium or potassiumn hydroxide diluted solution. The base is then extracted by a suitable organic solvent (for example halogenated solvents, esters, ethers), which is then dried. The organic solution is evaporated and then one proceeds according to the preceding preparation methods, by dissolving the base in acetonitrile or in the other above mentioned solvents. [0149]
  • The nitrate salts can be obtained also by using precursors of the described classes containing in the molecule a —ONO[0150] 2 group bound by a linking bridge prepared as described in the European patent 759,899 in the name of the Applicant herein incorporated by reference.
  • The following examples are given only for illustrative purposes and they are not a limitation of the same. [0151]
    • EXAMPLE 1 Timolol Nitrate Salt Preparation
  • To a saturated aqueous solution of sodium bicarbonate (100 ml) the timolol maleate salt (7 g) is added. The mixture is extracted with ethyl acetate (300 ml). The organic phase is dried by sodium sulphate and then evaporated under vacuum, obtaining the corresponding Timolol base (4.9 g) which is dissolved in acetonitrile (25 ml). The solution cooled with ice is treated with a 65% nitric acid solution (1.08 ml) in acetonitrile (5 ml) and after 30 minutes under stirring at cold it is treated with ethyl ether (100 ml) to give a solid which is filtered, washed with ethyl ether and dried under vacuum. 4.6 g of Timolol nitrate salt m.p. 115°-116° C. are obtained. [0152]
  • [0153] 1H-NMR (D2O) ppm: 4.34 (1H, m), 3.76 (4H, t), 3.39 (4H, t), 3.23 (2H, m), 3.04 (2H, m), 1.29 (9H, s).
    Elementary analysis (C13H25N5O6S):
    calc. (%) C 41.15 H 6.64 N 18.46 S 8.45
    found (%) C 41.24 H 6.61 N 18.38 S 8.31
    • EXAMPLE 2 Propranolol Nitrate Salt Preparation
  • To a saturated aqueous solution of sodium bicarbonate (70 ml) the propranolol hydrochloride salt (5 g) is added. The mixture is extracted with ethyl acetate (250 ml). The organic phase is dried by sodium sulphate and then evaporated under vacuum, obtaining the corresponding Propranolol base (4.2 g) which is dissolved in acetonitrile/tetrahydrofuran 5/2 (70 ml). The solution cooled with ice is treated with a 65% nitric acid solution (1.13 ml) in acetonitrile (10 ml) and after 30 minutes under stirring at cold it is treated with ethyl ether (50 ml) to give a solid which is filtered, washed with ethyl ether and dried under vacuum. 5.1 g of Propranolol nitrate salt m.p. 127°-130° C. are obtained. [0154]
  • [0155] 1H-NMR (D2O) ppm: 8.15 (1H, m), 7.80 (1H, m), 7.48-7.32 (4H, m), 6.86 (1H, d), 4.32 (1H, m) 4.13 (2H, d) 3.36 (1H, m), 3.22 (2H, d), 1.24 (6H, d).
    Elementary analysis (C16H22N2O5):
    calc. (%) C 59.62 H 6.88 N 8.69
    found (%) C 59.99 H 6.97 N 8.65
    • EXAMPLE 3 Sildenafil Nitrate Salt Preparation
  • A Sildenafil solution (7.7 g, 16.3 mmoles) in a mixture of acetonitrile (100 ml) and tetrahydrofuran (40 ml) is treated with 65% nitric acid (1.13 ml) dissolved in acetonitrile (10 ml). After 30 minutes at +4° C., it is concentrated to small volume by evaporation at reduced pressure and ethyl ether (100 ml) is slowly added. The formed precipitate is filtered, washed with ethyl ether and dried under vacuum. A white amorphous solid (6.5 g) is obtained. [0156]
    Elementary analysis (C22H31N7O7S):
    calc. (%) C 49.15 H 5.81 N 18.24 S 5.96
    found (%) C 49.34 H 5.75 N 18.38 S 6.00
    • EXAMPLE 4 Valsartan Nitrate Salt Preparation
  • A Valsartan solution (3.48 g, 8 mmoles) is prepared by dissolving in a mixture of acetonitrile (30 ml) and tetrahydrofuran (10 ml). Nitric acid diluted in acetonitrile is added at cold (2 ml taken from a solution obtained by adding to 2.7 ml of 65% nitric acid in acetonitrile and bringing to the final volume of 10 ml). After 30 minutes ethyl ether (100 ml) is slowly added at the same temperature (+4° C.). A precipitate is formed which is filtered, washed with ethyl ether and dried under vacuum. A white amorphous solid (3.1 g) is obtained. [0157]
    Elementary analysis (C24H30N6O6):
    calc. (%) C 57.82 H 6.07 N 16.86
    found (%) C 58.02 H 6.02 N 16.77
    • EXAMPLE 5 Hydralazine Nitrate Salt Preparation
  • Hydralazine hydrochloride (3 g) is added to a potassium carbonate aqueous solution (50 ml). It is extracted with ethyl acetate (80 ml). The organic phase is washed with water, dried by sodium sulphate and evaporated under vacuum. The residue (1 g, 6.25 mmoles) is dissolved in a mixture of acetonitrile (30 ml) and methanol (20 ml). It is cooled at +4° C. and a 65% nitric acid solution (0.6 g, 6.24 mmoles) in acetonitrile (10 ml) is added. A white precipitate is formed, which is filtered and dried under vacuum (1 g, m.p. 237°-243° C.). [0158]
    Elementary analysis (C8H9N5O3):
    calc. (%) C 43.05 H 4.06 N 31.38
    found (%) C 43.32 H 4.03 N 31.22
    • EXAMPLE 6 Nicardipine Nitrate Salt Preparation
  • A Nicardipine hydrochloride solution (0.1 g, 0.194 mmoles) in acetonitrile (20 ml) is treated in the dark with silver nitrate (0.33 g, 0.194 mmoles). By keeping under stirring at room temperature for 30 minutes, the precipitate is formed as a white solid. It is filtered, concentrated to half volume at a reduced pressure, cooled to +4° C. and it is treated with ethyl alcohol. The precipitate is filtered. It is dried. A yellow solid is obtained (0.05 g, m.p. 193°-198° C.). [0159]
    Elementary analysis (C26H30N4O9):
    calc. (%) C 57.56 H 5.57 N 10.33
    found (%) C 57.44 H 5.63 N 10.44
    • EXAMPLE 7 Verapamil Nitrate Salt Preparation
  • A Verapamil hydrochloride solution (3.44 g, 7 mmoles) in a mixture of acetonitrile (50 ml) and tetrahydrofuran (15 ml) is treated in the dark with silver nitrate (1.19 g, 7 mmoles). The solution is kept under stirring at room temperature for one hour. The precipitate is slowly formed and is filtered at the end. The solution is concentrated to half volume, cooled to +4° C. and the formed precipitate is filtered. After drying, a white amorphous solid is obtained (2.8 g). [0160]
    Elementary analysis (C27H39N3O7):
    calc. (%) C 62.65 H 7.59 N 8.12
    found (%) C 62.48 H 7.68 N 8.11
    • EXAMPLE 8 Amiloride Nitrate Salt Preparation
  • An amiloride hydrochloride solution (2 g, 7.5 mmoles) in methanol (100 ml) is treated with silver nitrate in the dark (1.28 g, 7.5 mmoles). A precipitate is quickly formed. It is left under stirring for 30 minutes at room temperature. Finally the solid is filtered and the solution is concentrated at reduced pressure to half of the initial volume. It is treated with ethyl ether (50 ml) and, after cooling at +4° C., the obtained solid is filtered. After drying a solid is separated (0.8 g, m.p. >280° C.). [0161]
    Elementary analysis (C6H9ClN8O4):
    calc. (%) C 24.63 H 3.10 N 38.29 Cl 12.11
    found (%) C 24.75 H 3.03 N 38.19 Cl 12.24
    • EXAMPLE 9 Study of the Effects of Propranolol, Propranolol Nitrate, Timolol and Timolol Nitrate on the Experimental Bronchoconstriction in the Guinea Pig
  • The compounds at a dose of 10 mg/kg and the corresponding carrier have been administered to the guinea pigs (groups of 6 animals each) by intraperitoneal route for three consecutive days. [0162]
  • The animals were prepared according to the method of Del Soldato et al. J. Pharmacol. Methods 5 279 1981. 45 minutes later 0.1 ml of a Capsaicin saline solution (1 μg/Kg) was injected to the anumals intravenously. The tidal air variation before and after the Capsaicin administration was measured by a Konzett apparatus, modified as described in the above mentioned reference, connected to a polygraphic system. [0163]
  • The effects of the compounds and of their corresponding nitrate salts on the experimental bronchoconstriction induced in guinea pigs by the Capsaicin injection are reported in Table 1. [0164]
    TABLE I
    Bronchoconstrictive
    effect
    Treatment (%)
    Carrier 100
    Timolol 188
    Timolol.HNO3 94
    Propranolol 280
    Propranolol.HNO3 110
    • EXAMPLE 10 Pharmacological Activity of Sildenafil Nitrate in Comparison with Sildenafil
  • The compounds have been administered in physiological solution. The control group has been treated with the carrier (physiologic solution) only. [0165]
  • The vaso-relaxing activity of Sildenafil nitrate was determined by using the experimental model of the prostatic deferent vessels constriction, induced by submaximum electric stimulation (D. A. Taylor et al., J. Pharmacol. Exp. Ther. 224, 40-45 1983), in rats treated with N[0166] W-nitro-L-arginine-methyl ester (L-NAME) as described by Ribeiro et al., Hypertension, 20, 298, 1992. Wistar adult male rats (235-284 g) for a period of 6 weeks received in drinking water L-NAME at a 60-70 mg/100 ml concentration, equivalent to a daily dose of about 60 mg/Kg. The animals received for five days by subcutaneous route a daily dose of 10 mg/kg of Sildenafil nitrate, of Sildenafil or of the carrier, respectively. One hour after the last treatment, the animals were sacrificed and the prostatic part of the deferent vessel was remouved, dipped in a physiologic solution at 37° C., and contracted by transmural stimulation (95% of the maximum stimulation, 0.2 Hz).
  • The reduction of the neurogenic contractive response, which results within 5 minutes from the addition of the tested substance at a concentration of 10[0167] −6 M, is taken as a measure of the vasorelaxing activity.
    TABLE II
    Effect on
    vasoconstriction
    Treatment (%)
    Carrier 100
    Sildenafil.HNO3 25
    Sildenafil 68
  • As it is evident from the Table, the myorelaxing activity of the nitrate salt is greater than that of the precursor reference compound. [0168]
  • The relaxation effect of the cavernous artery and of the human cavernosum corpora (vasodilating effect at a peripheric level) was also studied. It was used the technique described by R. G. Hempelmann et al., European Journal of Pharmacology 276, 277-280 (1995), employing erectile tissues coming from patients submitted to surgical operation. The cavernous arteries have been isolated and cleaned up from the surrounding connective tissue. Segments of about 2 mm length were obtained and were mounted in a myograph equipment. [0169]
  • After having drawn an experimental curve diameter/tension, the specimens have been adjusted to a diameter corresponding to 90% of the one reached in the presence of a transluminal pressure of 100 mm Hg; after a stabilization period of about 60 minutes, contraction was effected by adrenaline 3.10[0170] −6 M. After 15 minutes a dose corresponding to 10−6 M of each of the tested compounds was added and the relaxation percentage was recorded. The results are reported in Table III.
  • A second series of experiments has been carried out according to the same protocol, on the isolated strips, 3×3×5 mm, of cavernous tissue, isometrically suspended in baths for isolated organs, under a 5-10 mN tension. The results are reported in Table IV. [0171]
    TABLE III
    Relaxing effect on the isolated
    human cavernous artery precontracted
    with adrenaline (n = 5)
    Treatment (relaxation %)
    Sildenafil 10−6 M 25 ± 4
    SIN-1 10−6 M 36 ± 7
    Sildenafil.HNO3 10−6 M 61 ± 3
  • [0172]
    TABLE IV
    Relaxing effect on the isolated
    human cavernous tissue precontracted
    with adrenaline (n = 4)
    Treatment (relaxation %)
    Sildenafil 10−6 M 42 ± 6
    SIN-1 10−6 M 33 ± 4
    Sildenafil.HNO3 10−6 M 68 ± 7
  • In both the above experimental models it was evident a relaxation effect of the contraction induced by adrenaline both following to Sildenafil treatment, and to that with the nitric oxide SIN-1 donor. The derivative according to the present invention has shown an higher pharmacological effect than the precursor Sildenafil and SIN-1. [0173]
    • EXAMPLE 11 Study of the Antihypertensive and Anti-Angiotensinic Activity of Losartan Nitrate Compared with Losartan
  • The compounds have been administered in physiologic solution. The control group has been treated with the carrier (physiological solution) only. [0174]
  • The inhibiting effect of Losartan nitrate on the arterial hypertension has been assayed by using two experimental models: the arterial hypertension induced by L-NAME (see the preceding example) and the muscular contraction produced by Angiotensin II. In the first experiment Wistar adult male rats (235-284 g) received for 6 weeks drinking water containing L-NAME at a 60-70 mg/100 ml concentration, equivalent to a daily dose of about 60 mg/Kg. The animals received for five days subcutaneously a daily dose of 10 mg/kg of Losartan nitrate, Losartan or the carrier, respectively. One hour after the last treatment, the systemic arterial prssure was determined by caudal way, as described by Zatz, Lab. Anim. Sci., 42, 198, 1990. [0175]
  • In the second experiment (contraction produced by Angiotensin II), the method described by P. C. Wong et al., Hypertension, 13, 489-497, 1989 has been followed. Segments of the isolated ileum taken from guinea pigs (300-350 g) were dipped in a physiologic solution containing Angiotensin II (10 mcg/ml), Angiotensin II+Losartan nitrate 10[0176] −6M, and Angiotensin II+Losartan 10−6M, respectively. The results are reported in Table V.
    TABLE V
    Effect on the contraction
    Average arterial of the smooth
    pressure musculature
    Treatment (mm Hg) % (n = 5)
    Carrier 170 ± 7 100
    Losartan.HNO3 115 ± 4 12
    Losartan 153 ± 5 33
  • From the Table it is seen that the inhibiting effect of the nitrate salt on the hypertension produced by by L-NAME is greater than that of the precursor reference compound. The two products are both effective on myorelaxing activity since they inhibit the contraction induced by Angiotensin II, but the compound according to the invention shows an higher efficacy. [0177]
    • EXAMPLE 12 Study of the Antihypertensive and Vaso-Relaxing Activity of Minoxidil Nitrate Compared with Minoxidil
  • The compounds have been administered in a physiologic solution. The control group was treated with the carrier (physiologic solution) only. [0178]
  • The inhibiting effect of Minoxidil nitrate on the arterial hypertension has been determined by using two experimental models: the arterial hypertension induced by L-NAME (see Example 10) and the vascular contraction induced by electric stimulation. In the first pharmacological experiment the rats have been treated as described in the pharmacological experiment with L-NAME of Examnple 11. In the second experiment the method described by Taylor (see Example 10) has been followed as described before. The prostatic part of the isolated deferent duct of rats (200-220 g) was removed and dipped in a physiologic solution at 37° C. and then contracted by transmural stimulation (95% of the maximum stimulation, 0.2 Hz). [0179]
  • The vasorelaxing activity is expressed as the reduction of the contractive neurogenic response, determined within 5 minutes from the addition of the tested compound at a 10[0180] −6 M concentration.
    TABLE VI
    Average arterial Effect on the
    pressure vasoconstriction
    Treatment (mm Hg) % (n = 5)
    Carrier 170 ± 7 100
    Minoxidil.HNO3 110 ± 6 5
    Minoxidil 132 ± 6 18
  • As it is evident from Table VI, the inhibiting effect of Minoxidil nitrate salt on the hypertension produced by L-NAME in greater than that of the reference compound. As regards the vaso-relaxing activity, the two products are both effective in the inhibiting the vasoconstriction induced by the electric stimulation. [0181]
    • EXAMPLE 13 Study of the Antihypertensive and Beta-Adrenolytic Activity of Timolol Nitrate Compared with Timolol
  • Two experimental models were used: the arterial hypertension produced by L-NAME and the inotropic-positive effect caused by Isoprenaline. [0182]
  • In the former experiment the antihypertensive activity has been studied according to the experimental model described in Example 11. [0183]
  • In the latter experiment the method described by Grodzinski et al., Arch. Int. Phramacodyn., 191, 133-141, 1971 was followed. The left atrium specimens taken from guinea pigs (300-350 g) were maintained at 32° C. in a physiologic solution wherein the concentration of calcium ion was ⅓ lower and stimulated by Isoprenaline (10 mcg/ml). The beta-adrenolitic activity is expressed as the reduction of the inotropic-positive effect (increase of the cardiac muscle contraction) following addition of the compound under examination at a 10[0184] −6M concentration.
    TABLE VII
    Average arterial Inotropic positive
    pressure effect
    Treatment (mm Hg) % (n = 5)
    Carrier 170 ± 7 100
    Timolol.HNO3 108 ± 8 13
    Timolol 144 ± 5 32
  • As it is evident from Table VII, the inhibition effect of the Timolol nitrate salt on the hypertension produced by L-NAME is greater than yhat of Timolol. As regards the adrenolytic activity, the two products are both effective in inhibiting the inotropic-positive effect caused by Isoprenaline, but that according to the invention shows an higher efficacy. [0185]
    • EXAMPLE 14 Study of the Antihypetensive and Calcium Antagonist Activity of Nicardipine Nitrate Salt Compared with Nicardipine
  • Two experimental models were used: the arterial hypertension induced by L-NAME and the muscular contraction induced by calcium chloride. [0186]
  • In the former experiment the antihypertensive activity was studied according to the experimental model described in Example 11. [0187]
  • In the latter, the experimental model adapted was that of the ileal contraction caused by calcium chloride, according to the method described by M. J. Spedding, J. Pharmacology 83, 211-220, 1984. Ileus segments taken from guinea pig (300-350 g) were maintained at 37° C. in a physiologic solution not containing calcium ions and then stimulated by calcium chloride addition (final concentration 20 mcg/ml). The calcium antagonist activity was determined as the reduction of the ileal contraction following addition of each of the test compounds at a concentration 10[0188] −6 M.
    TABLE VIII
    Average arterial Contracturing
    pressure effect
    Treatment (mm Hg) % (n = 5)
    Carrier 170 ± 7 100
    Nicardipine.HNO3 108 ± 3 8
    Nicardipine 122 ± 6 25
  • As it is evident from the Table, the inhibiting effect of the nitrate salt on the hypertension induced by L-NAME is greater than that of the precursor Nicardipine. As regards the calcium antagonist activity the two compounds appeared both effective in inhibiting the contracturing calcium-depending effect, even if in a different extent. [0189]
    • EXAMPLE 15 Study of the Antihypertensive and Diuretic Activity in Rats of the Amiloride Nitrate Salt Compared with Amiloride
  • The Amiloride pharmacological profile has been determined by using the following experimental models: the arterial hypertension produced by L-NAME, and the diuretic effect. [0190]
  • In the former experiment the antihypertensive activity has been studied according to the experimental model described in Example 11. [0191]
  • In the latter experiment the diuretic effect was studied according to the method described by W. L. Lipschwitz et al. J. Pharmacol. Exp. Ther., 79, 97-110, 1943. No 3 groups of 6 rats (200-220 g) each, stalled in metabolic cages received drinking distilled water (25 ml/Kg p.o.). Each group was then subcutaneously injected with Amiloride nitrate (10 mg/Kg), Amiloride (10 mg/Kg) or carrier respecyively. The urine volume was collected during a period of 6 hours following drug administration, measured in ml. The diuretic effect is expressed as percentege of the collected urine volume calculated on that of the group treated with the carrier. [0192]
    TABLE IX
    Average arterial
    pressure Diuretic effect
    Treatment (mm Hg) % (n = 5)
    Carrier 170 ± 7 100
    Amiloride.HNO3 110 ± 5 215
    Amiloride 158 ± 7 220
  • As it is evident from Table IX, the inhibiting effect of the Amiloride nitrate salt on the hypertension induced by L-NAME, is remarkable over that of Amiloride. As regards the vaso-relaxing activity, the two compounds show similar diuretic activity. [0193]
    • EXAMPLE 16 Studies of Acute Toxicity of the Sildenafil and Zaprinast Salts with Nitric Acid
  • The two products have been administered in a suspension of carboxymethylcellulose 2%. [0194]
  • The acute toxicity of the above mentioned salts has been evaluated by oral administration of increasing doses of the compounds to groups of 10 rats each. Each group was administered of one dose. [0195]
  • The animals were kept under observation for 14 days. Lethality incidence and any toxic symptomatology was evaluated. [0196]
  • Even after administering of a 50 mg/Kg dose no sign of apparent toxicity was noticed. All the animals survived. [0197]
    • EXAMPLE 17 Studies of Gastric Toxicity of the Sildenafil and Zaprinast Salts with Nitric Acid in the Confront of that of the Precursors
  • 5 groups of Sprague-Dawley male rats (n=10), were fasted for 24 hours. 4 groups were then respectively treated i.p. with Sildenafil, Zaprinast, and the relevant nitrate salts of said drugs. One group was not treated and was tha control group. 30 minutes later 1 ml of ethanol 50% in water was given by os to the animals. [0198]
  • One hour later the animals were sacrificed. The stomach was removed and the gastric tissue was macroscopically examined. This examination was carried out by a researcher unaware of the treatments to which the rats had been subjected prior of sacrifice. The presence of lesions was checked as described by Gretzer et al. (Br. J. Pharmacol. 123, 927, 1998). [0199]
  • The results are reported in Table X. In the Table the gastric toxicity given as % incidence is the number of rats in a group showing gastric lesions. [0200]
    TABLE X
    Drug as free base Gastric toxicity
    Treatment mg/Kg/i.p. (% incidence)
    Controls 50
    Sildenafil 10 100
    Sildenafil.HNO3 10 20
    Zaprinast 10 90
    Zaprinast.HNO3 10 30
  • As noticed from the Table, in the groups of rats treated with Sildenafil or Zaprinast the gastric pathology was worsened with respect to the controls. The gastric toxicity of the corresponding nitrate salts of said drugs was lower than that of the control group. [0201]
    • EXAMPLE 18 Perhexiline Nitrate Preparation
  • Nitric acid 65% (0.75 ml) is added to a Perhexiline solution (3.02 g, 10.9 mmole) in acetonitrile and methanol (10 ml), cooled at 0° C. [0202]
  • The obtained solution is maintained under magnetic stirring at 0° C. for 30 minutes, then at room temperature for further 30 minutes. The solvent is evaporated under reduced pressure and the crude product is suspended in ethylic ether and then filtered. [0203]
  • The product (3.09 g) is obtained as white solid having melting point=151°-155° C. [0204]
    Elemental Analysis:
    C H N
    Calc. 67.00% 10.65% 8.26%
    Found 67.05% 10.79% 8.40%
    • EXAMPLE 19 Preparation of the salt Apomorphine Nitrate
  • Silver nitrate (2.72 g, 16 mmoles) was added to a solution of apomorphine hydrochloride (5 g, 16 mmoles) in acetonitrile (70 ml), and the mixture was stirred in the dark and under a nitrogen atmosphere for 30 minutes. Silver chloride was filtered out and the solution was diluted with diethyl ether. A precipitate was formed that was filtered, washed with diethyl ether and dried under vacuum. 4.3 g were recovered [0205]
    C, H, N analysis
    calc. (%) C 61.81 H 5.49 N 8.48
    found (%) C 61.84 H 5.45 N 8.51
    • EXAMPLE 20 Preparation of the Salt Zaprinast Nitrate
  • 0.5 ml of a solution nitric acid 65%/acetonitrile (2.7 ml/7.3 ml) was added at 0° C. to a solution of Zaprinast (0.5 g, 1.84 mmoles) in acetonitrile (10 ml) and the obtained mixture was stirred in the dark and under a nitrogen atmosphere for 30 minutes. The solution was then diluted with diethyl ether and the formed precipitate filtered, washed with diethyl ether and dried under vacuum. (0.4 g). [0206]
    C, H, N analysis
    calc. (%) C 46, 71 H 4, 22 N 25, 14
    found (%) C 46, 68 H 4, 26 N 25, 11

Claims (10)

What is claimed:
1. Nitrate salts of the compounds selected from the following classes:
Class (a1b) of formula (a1b):
Figure US20040147575A1-20040729-C00015
RI A1═—CH2OH,
R1 A1═H, Cl;
RII A1═—(CH2)3—CH3, —O—H2—CH3;
RIII A1═H, free valence;
RIV A1=free valence;
or RA1═—O and RIII A1=free valence form with the carbon atom in 5 position a keto group,
or RIV A1, RIII A1,RI A1 and the carbon atoms in 4 and 5 position of the heterocyclic ring of the formula (A1b) form group (IXc),
Figure US20040147575A1-20040729-C00016
or RI A1, RIV A1 and the carbon atom in 4 position of the heterocyclic ring of the formula (A1b) form group (1Xd);
Figure US20040147575A1-20040729-C00017
and wherein RIII A1=free valence and RIV A1=free valence there is a double bond between the carbon atoms in 4 and 5 position in the heterocyclic ring of the formula (A1b),
when XA1═(Ixa), RA1═CH2OH, RI A1═Cl, RIII A1═RIV A1=free valences forming a —CH═CH— double bond with the carbon atoms in 4 to 5 position of the heterocyclic ring of the formula (A1b), RII A1═—(CH2)3—CH3, Losartan residue;
as in Losartan but with RA1═—O and RIII A1 free valence, so as to form in combination with the carbon atom in 5 position of the heterocyclic ring of the formula (A1b) a ketonic group, RI A1 with RIV A1 and with the carbon atom in 4 position of the heterocyclic ring are such as to form the saturated ring having 5 carbon atoms (IXd), Irbesartan residue;
as in Losartan but with RII A1═—O—CH2—CH3, RA1 together with RI A1 and the carbon atoms in 4 and 5 position of the heterocyclic ring with RIV A1 and RIII A1 free valences, are such as to form the aromatic radical containing a —COOH group (IXc) Candesartan residue;
as in Losartan but with XA1═—COOH, RA1═(IXb), RI A1═H, and RIV A1 and RIII A1 free valence from a double bond between the carbon atoms in 4 and 5 position in the heterocyclic ring of formula (A1b), Eprosartan; class (A1c): Valsartan.
2. Nitrate salts of compounds selected from the following class (A3) of formula (A3):
Figure US20040147575A1-20040729-C00018
RVI B1═H;
RVII B1═H;
RI B1 and RII B1, equal to or different from each other, are H, CH3,
Figure US20040147575A1-20040729-C00019
wherein in the formula (XId) t=0, 1;
in the formula (XIe) YB1 can have the following meanings:
Figure US20040147575A1-20040729-C00020
in the formula (XIf) Z=H, —OCH3;
in the formula (A3);
XB1═—O—, —S—;
n and m, equal to or different from each other, are 0, 1;
Figure US20040147575A1-20040729-C00021
Figure US20040147575A1-20040729-C00022
wherein in the formula (XIp):
S1═H, CN, OCH3, CH3, —CH2—CH3—, —O—CH2—CONH—CH3, —COCH3, —CO—(CH2)2—CH3, —O—CH2—CH═CH2, —CH2—CH═CH2, cyclopentyl, or
Figure US20040147575A1-20040729-C00023
S2═H, CH3, Cl, —SOCH3, —CONH2; S3═H, F, Cl, OH, NO2, —CH2—CO—NH2, —(CH2)2—OCH3, —NH—COOH3, —CH2—O—CH2—CH2—O—CH(CH3)2, —CH2—CH2COOCH3, —NH—CO—N(C2H5)2, —NH—CO—(CH2)2—CH3, —NH—SO2—CH3, —NH—CO—NH-[cyclohexyl], —CH2—CH2—O—CH2-[cyclopropyl];
S4═H, Cl, —CH2—CH2—;
or S1, S2 and the carbon atoms in 2 and 3 position of the C6 aromatic ring of the radical (XIp) form the following ring:
Figure US20040147575A1-20040729-C00024
wherein:
(*) designates the atom adjacent to the aromatic ring of the formula XIpVII
B═—CH2—, —NH—, —CH═CH—, (*)-CO—CH2—;
A=-O—, (*)-CH2—CH(OH)—, (*)-O—CH2—, (*)-S—CH2—, —CH2CH2—, —CH2—,
W1═H, free valence;
W2=free valence, H, OH, —CH3, —ONO2, —O;
or A is a tertiary carbon atom and at the same time W1=free valence to form a double bond —CH═CH— between A and the carbon atom in 1′ position, or W1, W2 the carbon atom in 1′ position and A form an aromatic ring having 6 carbon atoms to form the following group:
Figure US20040147575A1-20040729-C00025
when W2═—O and W1=free valence at the carbon atom in 1′ position of radical (XIpVII) it is formed a ketonic group;
or when in formula (XIp) S4═—CH2—CH2—, and in formula (A3) XB1 is oxygen, m=n=1 and (RVII B1) is a free valence, the following ring is formed with the carbon atoms in 1 and 6 position of the aromatic ring of radical (XIp):
Figure US20040147575A1-20040729-C00026
or when in formula (A3) n=m=1, both RVII B1 and RVI B1 are free valences, S4 and the carbon atoms in 1 and 6 position of the aromatic ring of formula (XIp), S1 being —CH2—CH3, together with the carbon atom —|C|n— and XB1=oxygen of formula (A3) form the following ring:
Figure US20040147575A1-20040729-C00027
when RI B1═H, RII B1 and RIII B1═CH3, RV B1═H, RVI B1═RVII B1═H, m=n=1, XB1═—O—, RIV B1═(XIp) wherein S1═S2═S4═H, S3═—CH2—CO—NH2, Atenolol residue;
as in Atenolol but with RIV B1═(XIs), Befunolol residue;
as in Atenolol, but with S1═S2═S4═H, S1═—CH2—CH═CH2, Alprenolol residue;
as in Atenolol, but with S1═COCH3, S3═—NH—CO—(CH2)2—CH3, S2═S4═H, Acebutolol residue;
as in Atenolol, but with S3═—CH2—CH2—O—CH2-(cyclopropyl), Betaxolol residue;
as in Atenolol but with S3═—CH2—O—CH2—CH2—O—CH(CH3)2, Bisoprolol residue
as in Alprenolol but with S1═(XIpII) and RI B1═CH3, Bufetolol residue;
as in Bufetolol, but with S1═—CN, Bunitrolol residue;
as in Bufetolol, but with S1═H, S4═Cl, S2═CH3, Bupranolol residue;
as in Bufetolol but with S1═—CO—(CH2)2—CH3, S3═F, Butofilolol residue;
as in Mepindolol but in RIV B1═(XIpVII) A=-O—CH2—, B═—CH2—, W2=-ONO2,
W1=H, Nipradilol residue;
as in Alprenolol, but with S1═—O—CH2—CH═CH2, Oxprenolol residue;
as in Bufetolol, but with S1=cyclopentyl, Penbutolol residue;
as in Mepindolol but with W2=H, Pindolol residue;
as in Atenolol but with S3═—NH—COCH3, Practolol residue;
as in Bufetolol but with S1═H, S3═—NH—CO—NH-(cyclohexyl), Talinolol residue;
as in Nipradilol but with RI B1═CH3, A=-S—CH2— and W2=H, Tertatolol residue;
as in Tertatolol but with RIV B1═(XIn), Tilisolol residue;
as in Bufetolol but with RIV B1═(XIo), Timolol residue;
as in Bufetolol but with S1═S2═CH3, Xibenolol residue;
as in Xibenolol but with RI B1═S1═H, Toliprolol residue;
as in Toliprolol, but with RII B1═H and RIII B1═(XIa), Bevantolol residue;
as in Carazolol but with RII B1═H and RIII B1═(XIb), Carvedilol residue;
when in the formula (A3) RI B1═RII B1═RIII B1═CH3, RV B1═(XIh), n=m=1, RVI B1═RVII B1═H, XB1═—O—, RIV B1═(XIg), Bopindolol residue;
as in Atenolol but with RIV B1═(XIpVIII), wherein B═—NH—, Carazolol residue;
as in Bufetolol, but with RIV B1═(XIpVII) wherein A=-CH2—CH2—, B═—NH—, W2=-O which with W1=free valence and the carbon atom in 1′ position forms a ketonic group, Carteolol residue;
as in Bufetolol but with S3═—NH—CO—N(C2H5)2, S1═—CO—CH3 Celiprolol residue;
as in Bufetolol but with S1═—O—CH2—CONH—CH3, Cetamolol residue;
as in Bupranolol, but with S2═Cl Cloranolol residue;
as in Atenolol but with S3═—CH2—CH2—COOCH3, Esmolol residue;
as in Atenolol but with RIV B1═(Xiu) Indenolol residue;
as in Carteolol, but in RIV B1═(XIpVII) A=-CH2—, B═—COCH2—, W1=W2=H, Levobunolol residue;
as in Carteolol but with RI B1═H and in RIV B1═(XIpVII) A is a tertiary carbon atom and W1 free valence, so as to form a —CH═CH— double bond between A and the carbon atom in 1′ position of (XIpVII), W2=CH3, Mepindolol residue;
as in Atenolol, but with S3═—(CH2)2—OCH3, Metoprolol residue;
as in Carteolol but in RIV B1═(XIpVII) A=-CH2—CH(OH)—, B═—CH2—, W2=OH,
W1=H, Nadolol residue;
as in Atenolol but with S3═NO2, Nifenalol residue;
as in Bufetolol but with RIV B1═(XIt), Bucumolol residue;
when in the (A3) formula m=n=0 and RIV B1═(XIz) RI B1═RII B1═RIII B1═CH3, RV B1═H, Bufuralol residue;
as in Atenolol but with RIII B1═(XIe) with YB1═H, n=m=0, RIV B1═(XIi) Butidrine residue;
as in Butidrine, but with RIII B1═(XIe) with YB1═(XIf) with Z=H, RIV B1═(XIp)
wherein S3═OH and S2═CONH2, S1═S4═H, Dilevalol residue;
as in Bevantolol but with S2═H, S1═CN, RIII B1═(XIc), Epanolol residue;
as in Butidrine but with RIII B1═CH3, RIV B1═(XIm), wherein the naphthalenic residue is linked by the carbon atom in 2 position to the carbon atom bringing the —ORIV B1 substituent, Pronethalol residue;
as in Pronethalol but with m=1 and XB1═—O—, and RIV B1 is the naphthalenic residue (XIm) linked by the carbon atom in 1 position to XB1 Propranolol residue;
as in Pronethalol but with RIV B1═(XIp) with S1═S2═S4═H and S3═—NH—SO2—CH3, Sotalol residue;
as in Dilevalol but with S2═—SOCH3, and in para position to the other aromatic ring (form. XIf) Z=-OCH3, Sulfinalol residue;
when in the formula (A3) RI B1═RII B1═H, RIII B1═(XId) with t=1, RV B1═H, n=m=0, RIV B1═(XId) with t=0, Nebivolol residue;
2-hydroxy-5-[1-hydroxy-2-[(1-methyl-3-phenylpropyl)amino]ethyl]benzamide (Labetalol), 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-[(tetrahydro-2-furanyl)carbonyl]piperazine(Terazosin), 1-(4-amino-6,7-dimethoxy-2-quinazolinyl)-4-(2-furanylcarbonyl)piperazine (Prazosin).
3. Nitrate salts of the following compounds of class (A4):
(A4a):
(2S-cis)-3-(acetyloxy)-5-[2-(dimethylamino)ethyl]-2,3-di-hydro-2-(4-methoxyphenyl)-1,5-benzothiazepin-4(5H)-one (Diltiazem), α-[3-[[2-(3,4-dimethoxyphenyl)ethyl]-methylamino]propyl]-3,4-dimethoxy-α-(1-methylethyl)-benzeneacetonitrile (Verapamil);
(A4b):
2-[(2-aminoethoxy)methyl]-4-(2-chlorophenyl)-1,4-di-hydro-6-methyl-3,5-pyridynedicarboxylic acid 3-ethyl 5-methyl ester (Amlodipine), 4-(2,3-dichlorophenyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid methyl ester (Felodipine) 4-(4-benzofurazanyl)-1,4-dihydro-2,6-dimethyl-3,5-pyridinedicarboxylic acid 5-methyl 3-(1-methyl)ethyl ester (Isradipine), Lercanidipine, 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridine-dicarboxylic acid methyl 2[methyl(phenylmethyl)amino]ethyl ester (Nicardipine), 1,4-dihydro-2,6-dimethyl-4-(2-nitro-phenyl)-3,5-pyridinedicarboxilic acid dimethyl ester (Nifedipine), 1,4-dinhydro-2,6-dimethyl-4-(3-nitrophenil)-3,5-pyridinedicarboxylic acid 2-methoxyethyl 1-methylethyl ester (Nimodipine), 1,4-dihydro-2,6-dimethyl-4-(2-nitro-phenyl)-3,5-pyridinedicarboxylic acid methyl 2-methyl-propyl ester (Nisoldipine) 1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3,5-pyridinedicarboxylic acid ethyl methyl ester (Nitrendipine);
(A4c):
(E)-1-[bis(4-fluorophenyl)methyl]4-(3-phenyl-2-propenyl)piperazine (Flunarizine).
4. Nitrate salts of the following compounds of class (A7):
(A7a):
6-chloro-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide (Chlorothiazide), 2-chloro-5-(2,3-dihydro-1-hydroxy-3-oxo-1H-isoindol-1-yl)benzebesulphonamide (Chlortalidone), 6-chloro-3,4-dihydro-2H-1,2,4-benzothiadiazine-7-sulphonamide 1,1-dioxide (Hydrochlorothiazide), 3-(aminosulphonyl)-4-chloro-N-(2,3-dihydro-2-methyl-1H-indol-1-yl)benzamide (Indapamide), 7-chloro-1,2,3,4-tetrahydro-2-methyl-3-(2-methylphenyl)-4-oxo-6-quinazolinesulphonamide (Metolazone), 7-chloro-2-ethyl-1,2,3,4-tetra hydro-4-oxo-6-quinazolinesulphonamide (Quinethazone);
(A7d):
3,5-diamino-N-(aminoiminomethyl)-6-chloropyrazinecarboxamide (Amiloride), 6-phenyl-2,4,7-pteridinetriamine (Triamterene),3-(aminosulphonyl)-5-(butylamino)-4-phenoxy-benzoic acid (Bumetanide), 5-(amino sulphonyl)-4-chloro-2-[(2-furanylmethyl)amino]benzoic acid (Furosemide), N-[[(1-methylethyl)amino]carbonyl]-4-[(3-methylphenyl)amino]-3-pyridinesulphonamide (Torasemide);
(A8):
Apomorphine.
5. Nitrate salts according to claims 1-4 of the following compounds:
class A1b): Losartan;
Class A3): Atenolol, Labetalol, Timolol, Prazosin, Terazosin, Propranolol;
Class A4): Nicardipine, Nifedipine, Nimodipine;
Class A7): Chlorothiazide, Amiloride, Furosemide.
6. Salts according to claims 1-4, wherein the salts of said compounds contain at least one nitrate ion mole/compound mole.
7. Pharmaceutical compositions of the nitrate salts according to claims 1-4 and a pharmaceutically acceptable carrier.
8. A method for treating hypertension, said method comprising administering to a patient in need thereof a hypertension treating effective amount of at least one compound of claims 1-4.
9. A method for treating cardiovascular disease, said method comprising administering to a patient in need thereof a cardiovascular disease treating effective amount of at least one compound of claims 1-4.
10. A method for treating hypertension, said method comprising local administration to a patient in need thereof a hypertension treating effect amount of at least one compound of claims 1-4.
US10/671,746 1998-06-19 2003-09-29 Nitrate salts of antihypertensive medicines Abandoned US20040147575A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/671,746 US20040147575A1 (en) 1998-06-19 2003-09-29 Nitrate salts of antihypertensive medicines

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
ITMI98A001408 1998-06-19
IT1998MI001408A IT1301759B1 (en) 1998-06-19 1998-06-19 NITRATED SALTS OF ANTI-HYPERTENSIVE DRUGS
US09/719,164 US6645965B1 (en) 1998-06-19 1999-06-15 Nitrate salts of antihypertensive medicines
US10/671,746 US20040147575A1 (en) 1998-06-19 2003-09-29 Nitrate salts of antihypertensive medicines

Related Parent Applications (2)

Application Number Title Priority Date Filing Date
PCT/EP1999/004138 Division WO1999067231A1 (en) 1998-06-19 1999-06-15 Nitrate salts of antihypertensive medicines
US09/719,164 Division US6645965B1 (en) 1998-06-19 1999-06-15 Nitrate salts of antihypertensive medicines

Publications (1)

Publication Number Publication Date
US20040147575A1 true US20040147575A1 (en) 2004-07-29

Family

ID=11380283

Family Applications (2)

Application Number Title Priority Date Filing Date
US09/719,164 Expired - Fee Related US6645965B1 (en) 1998-06-19 1999-06-15 Nitrate salts of antihypertensive medicines
US10/671,746 Abandoned US20040147575A1 (en) 1998-06-19 2003-09-29 Nitrate salts of antihypertensive medicines

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US09/719,164 Expired - Fee Related US6645965B1 (en) 1998-06-19 1999-06-15 Nitrate salts of antihypertensive medicines

Country Status (17)

Country Link
US (2) US6645965B1 (en)
EP (1) EP1087953B1 (en)
JP (1) JP2002518492A (en)
KR (1) KR100460714B1 (en)
CN (1) CN1315945A (en)
AT (1) ATE282600T1 (en)
AU (1) AU770387B2 (en)
BR (1) BR9911305A (en)
CA (1) CA2335356A1 (en)
DE (1) DE69922001T2 (en)
ES (1) ES2234265T3 (en)
HU (1) HUP0102719A3 (en)
IL (1) IL139226A0 (en)
IT (1) IT1301759B1 (en)
RU (1) RU2235097C2 (en)
WO (1) WO1999067231A1 (en)
ZA (1) ZA200006136B (en)

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060014829A1 (en) * 2004-07-16 2006-01-19 Nitromed, Inc. Methods for reducing hospitalizations related to heart failure
US20080293724A1 (en) * 2006-02-17 2008-11-27 Nitromed, Inc. Methods Using Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate
US20090306081A1 (en) * 2006-05-16 2009-12-10 Letts L Gordon Solid Dosage Formulations of Hydralazine Compounds and Nitric Oxide Donor Compounds
US8226977B2 (en) 2004-06-04 2012-07-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
FR3065339A1 (en) * 2017-04-13 2018-10-19 Stmicroelectronics Sa TRANSMISSION LINE WITH DEVICE FOR LIMITING LOSSES BY DISAPPOINTMENT

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000078760A1 (en) * 1999-06-21 2000-12-28 The Biochemical Pharmaceutical Factory Of Zhuhai Sez Process for preparing sildenafil, and troche which comprises sildenafil and apomorphine
CA2383974A1 (en) 1999-09-08 2001-03-15 Nitromed Inc. Methods of treating and preventing congestive heart failure with hydralazine compounds and isosorbide dinitrate or isosorbide mononitrate
US7537785B2 (en) 1999-10-29 2009-05-26 Nitromed, Inc. Composition for treating vascular diseases characterized by nitric oxide insufficiency
US7235237B2 (en) 1999-10-29 2007-06-26 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
US7708989B2 (en) 1999-10-29 2010-05-04 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
AU780261B2 (en) 1999-10-29 2005-03-10 Nitromed, Inc. Methods of treating vascular diseases characterized by nitric oxide insufficiency
JP2001226372A (en) 1999-12-06 2001-08-21 Sumika Fine Chemicals Co Ltd Crystalline and crystallizing or crystallized rosartan acid adduct and method of purification of rosartan
IT1317735B1 (en) * 2000-01-26 2003-07-15 Nicox Sa SALTS OF ANTIMICROBIAL AGENTS.
DE60135560D1 (en) * 2000-07-19 2008-10-09 Novartis Ag VALSARTAN SALT
IT1318673B1 (en) * 2000-08-08 2003-08-27 Nicox Sa DRUGS FOR SEXUAL DYSFUNCTIONS.
IT1318674B1 (en) * 2000-08-08 2003-08-27 Nicox Sa DO IT FOR INCONTINENCE.
WO2002087508A2 (en) 2001-05-02 2002-11-07 Nitromed, Inc. Nitrosated and nitrosylated nebivolol and its metabolites, compositions and methods of use
CN1646140A (en) 2002-02-04 2005-07-27 阿尔法玛药品研发有限公司 Use of a compound having the ability to release CO in preparation of pharmaceutical compositions for treatment of inflammation
EP1950204A1 (en) 2003-03-17 2008-07-30 Teva Pharmaceutical Industries Ltd. Amorphous form of valsartan
US7199144B2 (en) 2003-04-21 2007-04-03 Teva Pharmaceuticals Industries, Ltd. Process for the preparation of valsartan and intermediates thereof
US20040242661A1 (en) 2003-03-17 2004-12-02 Igor Rukhman Polymorphs of valsartan
EP1618097A1 (en) 2003-04-21 2006-01-25 Teva Pharmaceutical Industries Ltd Process for the preparation of valsartan
AU2004266705A1 (en) * 2003-08-20 2005-03-03 Nitromed, Inc. Nitrosated and nitrosylated cardiovascular compounds, compositions and methods of use
AU2004270162B2 (en) 2003-08-28 2010-05-13 Nicox S.A. Nitrosated ad nitrosylated diuretic compouds, compositions and methods of use
WO2005077374A1 (en) * 2004-02-06 2005-08-25 Becton, Dickinson And Company Formulations of phosphodiesterase 5 inhibitors and methods of use
TW200613275A (en) * 2004-08-24 2006-05-01 Recordati Ireland Ltd Lercanidipine salts
AU2005304770A1 (en) * 2004-11-08 2006-05-18 Nicox S.A. Nitrosated and nitrosylated compounds, compositions and methods for the treatment of ophthalmic disorders
WO2006079610A1 (en) * 2005-01-31 2006-08-03 Nicox S.A. Nitrooxy sartan derivatives as angiotensin ii receptor blockers for the treatment of cardiovascular and inflammatory diseases
JP2008531579A (en) 2005-02-24 2008-08-14 ニトロメッド インコーポレーティッド Nitric oxide enhanced diuretic compounds, compositions and methods of use
EP2043607A2 (en) * 2006-06-23 2009-04-08 Usv Limited Process for the preparation of micronized valsartan
CA2960254A1 (en) 2008-08-01 2010-02-04 Arca Biopharma, Inc. Methods and compositions involving (s)-bucindolol
CN101987833B (en) * 2009-08-04 2014-07-30 北京利乐生制药科技有限公司 Novel nilvaldipine crystal types and preparation method thereof
WO2012056294A1 (en) 2010-10-29 2012-05-03 Jubilant Life Sciences Ltd. An improved process for the preparation of n-pentanoyl-n-[[2'-(1h-tetrazol-5-yi)[1,1'-biphenyl]-4-yi]methyl]-l-valine
EP2699242B1 (en) 2011-04-19 2017-11-01 Alfama, Inc. Carbon monoxide releasing molecules and uses thereof
CN102793705A (en) * 2011-05-25 2012-11-28 苏州洪瑞医药科技有限公司 Preparation method for compound film coated tablets of valsartan and cyclopenthiazide
JP6134710B2 (en) 2011-07-21 2017-05-24 アルファーマ インコーポレイテッドＡｌｆａｍａ，Ｉｎｃ． Ruthenium monoxide releasing molecules and uses thereof
CN104758293A (en) * 2014-01-02 2015-07-08 江苏吉贝尔药业有限公司 Method for preparing novel compound anti-hypertension preparation
CN105669532B (en) * 2014-12-03 2018-11-02 广州市恒诺康医药科技有限公司 Nimodipine soluble derivative and its preparation method and application
CN104758290A (en) * 2015-03-09 2015-07-08 西安力邦肇新生物科技有限公司 A compound antihypertensive composition and applications thereof
WO2017168174A1 (en) 2016-04-02 2017-10-05 N4 Pharma Uk Limited New pharmaceutical forms of sildenafil
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7115581A (en) * 1970-11-13 1972-05-16 Dresden Arzneimittel
US5250534A (en) * 1990-06-20 1993-10-05 Pfizer Inc. Pyrazolopyrimidinone antianginal agents
ATE184589T1 (en) * 1994-05-10 1999-10-15 Nicox Sa NITRO COMPOUNDS AND PREPARATIONS THEREOF HAVING ANTI-INFLAMMATORY, PAIN-RELIEVING AND ANTITHROMBOTIC EFFECTS
US5958926A (en) * 1996-11-01 1999-09-28 Nitromed, Inc. Nitrosated and nitrosylated phosphodiesterase inhibitor compounds, compositions and their uses
IT1295694B1 (en) * 1996-11-14 1999-05-27 Nicox Sa NITROXIS DERIVATIVES FOR THE PREPARATION OF MEDICATIONS WITH ANTI-THROMBINIC ACTIVITY
IT1292426B1 (en) * 1997-06-27 1999-02-08 Nicox Sa NITRATED SALTS OF ACE-INHIBITORS

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8226977B2 (en) 2004-06-04 2012-07-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US8414920B2 (en) 2004-06-04 2013-04-09 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition containing irbesartan
US20060014829A1 (en) * 2004-07-16 2006-01-19 Nitromed, Inc. Methods for reducing hospitalizations related to heart failure
US20060014828A1 (en) * 2004-07-16 2006-01-19 Nitromed, Inc. Compositions and methods related to heart failure
US20090118293A1 (en) * 2004-07-16 2009-05-07 Nitromed, Inc. Methods for reducing hospitalizations related to heart failure
US20090118294A1 (en) * 2004-07-16 2009-05-07 Manuel Worcel Compositions and methods related to heart failure
US20080293724A1 (en) * 2006-02-17 2008-11-27 Nitromed, Inc. Methods Using Hydralazine Compounds and Isosorbide Dinitrate or Isosorbide Mononitrate
US20090306081A1 (en) * 2006-05-16 2009-12-10 Letts L Gordon Solid Dosage Formulations of Hydralazine Compounds and Nitric Oxide Donor Compounds
FR3065339A1 (en) * 2017-04-13 2018-10-19 Stmicroelectronics Sa TRANSMISSION LINE WITH DEVICE FOR LIMITING LOSSES BY DISAPPOINTMENT
US10236865B2 (en) 2017-04-13 2019-03-19 Stmicroelectronics Sa Transmission line with device for limiting losses through impedance mismatch
US10715113B2 (en) 2017-04-13 2020-07-14 Stmicroelectronics Sa Transmission line with device for limiting losses through impedance mismatch

Also Published As

Publication number Publication date
IL139226A0 (en) 2001-11-25
EP1087953A1 (en) 2001-04-04
DE69922001T2 (en) 2005-11-03
ATE282600T1 (en) 2004-12-15
AU4513999A (en) 2000-01-10
HUP0102719A2 (en) 2001-12-28
RU2235097C2 (en) 2004-08-27
BR9911305A (en) 2001-10-23
CA2335356A1 (en) 1999-12-29
CN1315945A (en) 2001-10-03
AU770387B2 (en) 2004-02-19
HUP0102719A3 (en) 2002-11-28
IT1301759B1 (en) 2000-07-07
KR20010093631A (en) 2001-10-29
ES2234265T3 (en) 2005-06-16
US6645965B1 (en) 2003-11-11
ITMI981408A1 (en) 1999-12-19
JP2002518492A (en) 2002-06-25
EP1087953B1 (en) 2004-11-17
ZA200006136B (en) 2002-01-30
WO1999067231A1 (en) 1999-12-29
KR100460714B1 (en) 2004-12-09
DE69922001D1 (en) 2004-12-23

Similar Documents

Publication Publication Date Title
US6645965B1 (en) Nitrate salts of antihypertensive medicines
RU2000131690A (en) NITRATE SALTS OF HYPOTENSIC MEDICINES
CA2158108C (en) Compositions containing sertraline and a 5-ht1d receptor agonist or antagonist
AT396685B (en) METHOD FOR PRODUCING NEW 1,4-DISUBSTITUTED PIPERAZINE DERIVATIVES
JP2667987B2 (en) Method for producing 5- [2- (4- (benzoisothiazol-3-yl) -piperazin-1-yl) ethyl] -6-chloro-1,3-dihydro-indol-2-one and intermediate for production
LU84011A1 (en) 2-PHENOXYALKYL-1,2,4-TRIAZOL-3-ONES ANTIDEPRESSIVE
US5001134A (en) Piperidines, processes of preparation and medications containing them
JP2840288B2 (en) Substituted 1- (1H-imidazol-4-yl) alkyl-benzamide
JPH0770112A (en) Tetrazole derivative
US3948894A (en) 3-Amino-5,6-diaryl-1,2,4-triazines
EP0406739A2 (en) Piperidine derivative, method for preparation thereof, and a pharmaceutical composition comprising the same
HU201730B (en) Process for producing indane derivatives and pharmaceutical compositions comprising same
TWI254712B (en) Novel piperidine derivatives, process for obtaining them and pharmaceutical compositions containing them
JP3093419B2 (en) 1,4-benzothiazepine derivatives
US4612329A (en) Pharmaceutical alpha-aminoalkyl-alpha-alkylphenylacetonitriles
US4384140A (en) 2-Chloroethyl urea derivatives
US4367239A (en) Nitrosourea derivatives, pharmaceutical compositions thereof and method of preparation
JP2856912B2 (en) Alkyl derivatives of trazodone exhibiting CNS activity
EP0197386B1 (en) 2-(substituted sulfamyl) derivatives of 6-nitrobenzoic acid, process for their preparation and pharmaceutical compositions containing them
JP2625294B2 (en) Piperidine derivative
US3969356A (en) N-[3-(p-f-benzoyl)-propyl]-N'-[2.(nitro,nitro-el, or methoxyphenyl)-ethyl]-p
HU194193B (en) Process for preparing new 4-/amino-methylidene/-3-aryl-5/4h/-isoxazolinone derivatives and pharmaceutical compositions containing such compounds as active ingredients
EP0157762B1 (en) New substituted piperidinoguanidines, preparation process and pharmaceutical compositions containing them
US4694020A (en) Derivatives of 2-(substituted sulfamyl)-6-nitrobenzoic acids and pharmaceutical compositions
KR850000274B1 (en) Process for preparing naphthimidazoles and naphthoxazoles

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION